Calliditas announces publication of cost-effectiveness analysis on Nefecon

Calliditas Therapeutics announced the publication of a cost-effective analysis of Nefecon versus standard of care for people with Primary IgA Nephropathy in the United States. The analysis was published in the peer-reviewed journal ClinicoEconomics and Outcomes Research. Researchers used a health-state transition model to estimate the cost-effectiveness of Nefecon in addition to the SOC versus SOC alone in adult patients with primary IgAN in the US. Health-state occupancy probabilities and key model inputs were based on the individual patient-level data from NefIgArd, the Phase 3 randomized controlled trial evaluating Nefecon. Based on commonly accepted willingness to pay thresholds in the US, the research analyzed cost-effectiveness data for Nefecon and demonstrated an incremental cost-effectiveness ratio of $15,428/QALY in a deterministic analysis, likely explained by estimated time spent in less severe stages of kidneys disease.